State Of Wyoming Mirati Therapeutics, Inc. Transaction History

State Of Wyoming

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $1,135 - $2,572	29 Added 31.87%	120 $8,000
Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $1,137 - $2,264	15 Added 19.74%	91 $7,000
Q4 2021 Feb 11, 2022	SELL	$132.01 - $190.29 $528 - $761	-4 Reduced 5.0%	76 $11,000
Q3 2021 Feb 11, 2022	SELL	$132.13 - $177.45 $5,153 - $6,920	-39 Reduced 32.77%	80 $14,000
Q2 2021 Feb 11, 2022	BUY	$144.0 - $179.73 $9,072 - $11,322	63 Added 112.5%	119 $19,000
Q1 2021 Feb 08, 2022	BUY	$158.92 - $221.61 $8,899 - $12,410	56 New	56 $10,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.